The purpose of this study is to demonstrate superior efficacy of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of patients with schizophrenia.

Condition	Treatment or Intervention	Phase
Schizophrenia	Drug: quetiapine fumarate tablets	Phase III

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Patient is able to provide written informed consent before beginning any study related procedures
• Patient has a documented clinical diagnosis of schizophrenia
• Patient is able to understand and comply with the requirements of the study, as judged by a study investigator

Exclusion Criteria:

• Patients with a history of non-compliance as judged by the study investigator
• Patients with a known lack of response to previous treatment with quetiapine
• Patients who have participated in another drug study within 4 weeks prior to enrollment into this study
• Patients who have previously participated in this study or study D1444C00132

AstraZeneca Information Center (8a-7P EST) 001-800-236-9933 (Outside US)      800-236-9933 

Alabama
      Research Site, Birmingham,  Alabama,  United States; Recruiting
California
      Research Site, Cerritos,  California,  United States; Recruiting
      Research Site, Rosemead,  California,  United States; Recruiting
      Research Site, San Diego,  California,  United States; Recruiting
      Research Site, Santa Ana,  California,  United States; Recruiting
      Research Site, Pico Rivera,  California,  United States; Recruiting
      Research Site, Culver City,  California,  United States; Recruiting
      Research Site, Anaheim,  California,  United States; Not yet recruiting
      Research Site, Riverside,  California,  United States; Not yet recruiting
District of Columbia
      Research Site, Washington,  District of Columbia,  United States; Recruiting
Florida
      Research Site, Miami,  Florida,  United States; Recruiting
      Research Site, Bradenton,  Florida,  United States; Not yet recruiting
Illinois
      Research Site, Oakbrook Terrace,  Illinois,  United States; Recruiting
      Research Site, Hoffman Estates,  Illinois,  United States; Not yet recruiting
Louisiana
      Research Site, New Orleans,  Louisiana,  United States; Recruiting
Maryland
      Research Site, Baltimore,  Maryland,  United States; Not yet recruiting
      Research Site, Rockville,  Maryland,  United States; Not yet recruiting
Mississippi
      Research Site, Jackson,  Mississippi,  United States; Recruiting
Missouri
      Research Site, St. Louis,  Missouri,  United States; Recruiting
New Jersey
      Research Site, Clementon,  New Jersey,  United States; Recruiting
New York
      Research Site, Holliswood,  New York,  United States; Recruiting
      Research Site, Lawrence,  New York,  United States; Recruiting
      Research Site, Staten Island,  New York,  United States; Recruiting
Ohio
      Research Site, Medina,  Ohio,  United States; Recruiting
Oklahoma
      Research Site, Oklahoma City,  Oklahoma,  United States; Recruiting
Pennsylvania
      Research Site, Philadelphia,  Pennsylvania,  United States; Recruiting
      Research Site, Norristown,  Pennsylvania,  United States; Recruiting
South Dakota
      Research Site, Sioux Falls,  South Dakota,  United States; Recruiting
Tennessee
      Research Site, Memphis,  Tennessee,  United States; Recruiting
Texas
      Research Site, Austin,  Texas,  United States; Recruiting
      Research Site, Houston,  Texas,  United States; Recruiting
      Research Site, Irving,  Texas,  United States; Recruiting
      Research Site, San Antonio,  Texas,  United States; Recruiting
      Research Site, Desoto,  Texas,  United States; Not yet recruiting
Virginia
      Research Site, Richmond,  Virginia,  United States; Recruiting
      Research Site, Falls Church,  Virginia,  United States; Recruiting
Washington
      Research Site, Kirkland,  Washington,  United States; Recruiting

Study ID Numbers:  D1444C00133
Record last reviewed:  March 2005
Last Updated:  March 21, 2005
Record first received:  June 16, 2004
ClinicalTrials.gov Identifier:  NCT00085891
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08